• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

给猴子输注负载红细胞的天冬酰胺酶。免疫学、代谢学及毒理学后果。

Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.

作者信息

Updike S J, Wakamiya R T

出版信息

J Lab Clin Med. 1983 May;101(5):679-91.

PMID:6187874
Abstract

In order to evaluate enzyme loading of RBCs as a drug delivery system, the antitumor agent asparaginase was loaded into the erythrocytes of nine monkeys at three different doses and autologously injected back into these animals. Nine control monkeys were also once injected intravenously at the same doses of enzyme, but the enzyme was free in solution rather than entrapped in RBCs. The RBCs and asparaginase were labeled with 51Cr and 125I, respectively. The circulating half-life of the enzyme-loaded, resealed RBCs was 7 days, as compared to 9 days in the control RBCs. Beginning at 5 days, circulating enzyme activity was several orders of magnitude higher in the monkeys injected with RBC-loaded asparaginase than in controls. Targeting of drug-loaded RBCs into the spleen and liver was apparent. Suppression of the serum substrate level of asparaginase in the monkeys treated with the single intravenous injection of RBCs loaded with asparaginase was 20 days, which was twice as long as the suppression in the control monkeys. Production of anti-asparaginase antibody was shown to reach a higher level and persist longer in the monkeys with RBC-entrapped asparaginase. Evidence was also obtained showing that entrapping asparaginase in RBCs protects against anaphylaxis in the guinea pig. Thus this drug delivery system is also proposed as a strategy to avoid life-threatening allergic reactions. Advantages and limitations of RBC loading as a drug delivery system are discussed.

摘要

为了评估红细胞作为药物递送系统的酶负载情况,将抗肿瘤药物天冬酰胺酶以三种不同剂量负载到九只猴子的红细胞中,并将其自体回注到这些动物体内。另外九只对照猴子也以相同的酶剂量进行了一次静脉注射,但酶是游离于溶液中而非包裹在红细胞内。红细胞和天冬酰胺酶分别用51Cr和125I进行标记。负载酶的重封红细胞的循环半衰期为7天,而对照红细胞为9天。从第5天开始,注射负载天冬酰胺酶红细胞的猴子体内循环酶活性比对照组高出几个数量级。负载药物的红细胞明显靶向到脾脏和肝脏。单次静脉注射负载天冬酰胺酶红细胞的猴子血清中天冬酰胺酶底物水平的抑制时间为20天,是对照猴子的两倍。结果显示,在红细胞包裹天冬酰胺酶的猴子体内,抗天冬酰胺酶抗体的产生达到更高水平且持续时间更长。还获得了证据表明,将天冬酰胺酶包裹在红细胞中可防止豚鼠发生过敏反应。因此,这种药物递送系统也被提议作为一种避免危及生命的过敏反应的策略。本文讨论了红细胞负载作为药物递送系统的优缺点。

相似文献

1
Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.给猴子输注负载红细胞的天冬酰胺酶。免疫学、代谢学及毒理学后果。
J Lab Clin Med. 1983 May;101(5):679-91.
2
Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.
Bibl Haematol. 1985(51):65-74.
3
Determination of parameters for enzyme therapy using L-asparaginase entrapped in canine erythrocytes.使用包裹在犬红细胞内的L-天冬酰胺酶进行酶疗法的参数测定。
Biotechnol Appl Biochem. 1988 Aug;10(4):365-72.
4
L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.恒河猴和人类脑脊液中L-天冬酰胺酶的药代动力学及天冬酰胺水平
Cancer Res. 1981 Nov;41(11 Pt 1):4554-8.
5
Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons.狒狒体内经核黄素-紫外线处理的红细胞的潜在免疫反应及存活情况评估。
Transfusion. 2009 Jan;49(1):64-74. doi: 10.1111/j.1537-2995.2008.01940.x. Epub 2008 Oct 14.
6
Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.凝胶包封的L-天冬酰胺酶:动力学行为和抗肿瘤活性。
J Pharmacol Exp Ther. 1975 Nov;195(2):382-8.
7
Slow release properties and liver-targeting characteristics of methotrexate erythrocyte carriers.甲氨蝶呤红细胞载体的缓释特性及肝靶向特性
Fundam Clin Pharmacol. 2009 Apr;23(2):189-96. doi: 10.1111/j.1472-8206.2008.00656.x. Epub 2009 Mar 9.
8
Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells.负载于人类红细胞中的L-天冬酰胺酶的药效学改善。
Eur J Clin Pharmacol. 1996;49(6):465-70. doi: 10.1007/BF00195932.
9
Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods.输血后红细胞的存活情况:不同储存期红细胞浓缩液的比较。
Transfusion. 2008 Jul;48(7):1478-85. doi: 10.1111/j.1537-2995.2008.01734.x. Epub 2008 May 13.
10
Synthesis, characterization and immunogenicity of silk fibroin-L-asparaginase bioconjugates.丝素蛋白-L-天冬酰胺酶生物共轭物的合成、表征及免疫原性
J Biotechnol. 2005 Nov 21;120(3):315-26. doi: 10.1016/j.jbiotec.2005.06.027. Epub 2005 Aug 15.

引用本文的文献

1
Ammonium removal by erythrocyte-bioreactors based on glutamate dehydrogenase from Proteus sp. jointly with porcine heart alanine aminotransferase.基于变形杆菌谷氨酸脱氢酶与猪心丙氨酸氨基转移酶的红细胞生物反应器去除铵。
Sci Rep. 2022 Mar 31;12(1):5437. doi: 10.1038/s41598-022-09435-y.
2
Erythrocytes as Carriers of Therapeutic Enzymes.红细胞作为治疗性酶的载体。
Pharmaceutics. 2020 May 8;12(5):435. doi: 10.3390/pharmaceutics12050435.
3
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.载药红细胞技术的最新进展和临床应用
BioDrugs. 2020 Jun;34(3):265-272. doi: 10.1007/s40259-020-00415-0.
4
Erythrocytes as Carriers: From Drug Delivery to Biosensors.红细胞作为载体:从药物递送 to 生物传感器。 (注:这里“to”原文有误,可能应是“到”的意思,按照正确理解完整译文应该是“红细胞作为载体:从药物递送到生物传感器” )
Pharmaceutics. 2020 Mar 18;12(3):276. doi: 10.3390/pharmaceutics12030276.
5
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood.用于治疗性靶向血液中癌细胞的纳米生物技术。
Cell Mol Bioeng. 2015;8(1):137-150. doi: 10.1007/s12195-015-0381-z. Epub 2015 Feb 24.
6
Biological gene delivery vehicles: beyond viral vectors.生物基因递送载体:超越病毒载体
Mol Ther. 2009 May;17(5):767-77. doi: 10.1038/mt.2009.41. Epub 2009 Mar 10.
7
In vivo half life of nanoencapsulated L-asparaginase.纳米包封的L-天冬酰胺酶的体内半衰期。
J Mater Sci Mater Med. 2002 Dec;13(12):1113-21. doi: 10.1023/a:1021125617828.
8
Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells.负载于人类红细胞中的L-天冬酰胺酶的药效学改善。
Eur J Clin Pharmacol. 1996;49(6):465-70. doi: 10.1007/BF00195932.
9
Carrier erythrocytes. Clinical pharmacokinetic considerations.载体红细胞。临床药代动力学考量。
Clin Pharmacokinet. 1993 Nov;25(5):351-7. doi: 10.2165/00003088-199325050-00001.